Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 72 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16000
Sealed predictions
- KMT2E in dopamine neurons, braak+0.23 (p 0.553) → -0.52 (p 0.154)receipt 16008
Swarm cases
receipt 16008: KMT2E in dopamine neurons, braak
- power
- full sample -0.18 (p 0.487, n 18), 95% CI -0.59 to +0.32. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.18 (p 0.487, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.25 (p 0.315, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.08, sign flips 0; without severely affected donors -0.18 (p 0.487, n 18). fragile.
- cell type
- strongest in OPCs: -0.59 (p 0.0099, n 18) vs -0.18 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KMT2E in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up KMT2E · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.50 p 0.076 (needs p < 1.4e-4)
Receipts
loading the receipts